Bio-Quant Creates GPCR-Screening Division | GenomeWeb

NEW YORK, Sept. 5 - Bio-Quant has created a new division designed to offer screening technology for G protein-coupled receptors, the company said on Wednesday.

GPCRs function as the delivery mechanism for more than 50 percent of all drugs currently on the market. To facilitate the discovery of additional GPCRs that might serve as drug targets, Bio-Quant’s new business unit will provide platforms that screen for cell motility and GPCR activation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.